Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of VG2025 in intrahepatic cholangiocarcinoma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• VG2025

Snippet

Sponsor: Virogin Biotech Ltd. | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING